Treating Mercury Toxicity with Emeramide - Interview with Boyd Haley

2019 Interview

Using nucleotide photoaffinity labeling technology, Boyd Haley, Ph.D., showed that mercury is the only heavy metal capable of causing a normal brain to develop the same biochemical abnormalities found in Alzheimer’s disease.

The enzyme creatine kinase is 98% inhibited in Alzheimer’s patients, and tubulin is inhibited by more than 80%.

Mercury causes the synaptic clefts to disappear and triggers the formation of neurofibrillary tangles, a major diagnostic hallmark of Alzheimer’s, by causing abnormal hyperphosphorylation of tau.

The chelating compound Haley developed, called emeramide or NBMI, tightly binds to mercury and expels it through your stool.

Phase I and Phase II drug trials has shown emeramide significantly lowers mercury burden in animals and humans; the drug is still going through the approval process; it is designated as an orphan drug for use as a mercury chelator in both the U.S. and the European Union.

Article link: https://bit.ly/3X27VPY

Subscribe for FREE to the latest health news: https://bit.ly/3JVo3fB

Website: https://bit.ly/3TYWerq

Podcast: https://bit.ly/3JSWsvB

Facebook: https://www.facebook.com/doctor.health/
Instagram: https://www.instagram.com/drmercola
Twitter: https://twitter.com/mercola
Telegram: https://t.me/DoctorMercola
Truth: https://truthsocial.com/@Mercola
Gab: https://gab.com/Mercola
Gettr: https://gettr.com/user/mercola
Mewe: https://mewe.com/p-front/dr.josephmercola